R-Pharm Germany GmbH

Primary objectives: To evaluate the dose-response relationship of Enpatoran in reducing disease activity based on CLASI-A; To evaluate the dose-response relationship of Enpatoran in reducing disease activity based on BICLA response rate; Secondary objectives: To evaluate the safety and tolerability of Enpatoran compared with placebo; To evaluate the efficacy of Enpatoran compared with placebo in disease control in lupus subjects with active lupus rash; To demonstrate that Enpatoran is more effective than placebo in patients receiving ≥10 days of prednisone on day 1. mg in achieving BICLA response and clinically meaningful CS reduction in SLE subjects; Evaluate the effectiveness of Enpatoran compared with placebo in disease control in lupus subjects with active lupus rash; Evaluate the effectiveness of Enpatoran compared with placebo in disease control in active SLE subjects; Evaluate the effectiveness of Enpatoran compared with placebo in patient-reported symptoms and functional status in lupus subjects with active lupus rash; Evaluate the effectiveness of Enpatoran compared with placebo in patient-reported symptoms in active SLE subjects. And related exploratory objectives.